A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Other: Placebo
Biological: Benralizumab 100 mg
Biological: Benralizumab 25 mg
Biological: Benralizumab 200 mg

Registration Number: NCT00783289

Lead Sponsor: MedImmune LLC

Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.

Detailed Description: This is a Phase 2a, randomized, double-blind, placebo-controlled, dose-escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of multiple subcutaneous doses (25, 100, or 200 milligram \[mg\]) of benralizumab (MEDI-563) in adult subjects with asthma.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 35

Inclusion Criteria

Male or female subjects
Age 18 through 80 years at screening
Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
Previously documented diagnosis of asthma of more than or equal to (>=) 1 year duration, based on episodic symptoms of airflow obstruction; post-bronchodilator reversibility of airflow obstruction >=12 percent (%) (at screening or documented within 1 year prior to randomization); or proof of a positive response to a methacholine challenge (documented within 1 year prior to randomization) as represented by a provoking concentration of methacholine to cause a 20% fall in forced expiratory volume in 1 second (FEV1); (PC20) less than (<) 8 milligram per milliliter (mg/mL)
Weight of >=45 kilogram (kg) but less than or equal to (<=) 135 kg (>=100 pounds [lb] but <=300 lb)
Able to produce spirometry readings that meet American Thoracic Society (ATS)/European Respiratory Society (ERS) standards
Screening pre-bronchodilator FEV1 >=60%
Women of childbearing potential, unless surgically sterile (including tubal ligation) and/or at least 2 years post-menopausal, must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of a condom with spermicide by the sexual partner, or sterile sexual partner) for 14 days prior to the first dose of the investigational product on Study Day 0, and must agree to continue using such precautions through Study Day 161. Cessation of birth control after this point should be discussed with a responsible physician
Men, unless surgically sterile, must likewise use 2 effective methods of birth control (for example, condom with spermicide) and must agree to continue using such contraceptive precautions through End of Study/Study Day 161
Ability to complete the study period, including follow-up period until Study Day 161 as required by protocol

Exclusion Criteria

Previously received benralizumab (MEDI-563)
History of allergy or reaction to any component of the investigational product formulation
History of allergy or reaction to any other marketed or experimental monoclonal antibody therapies, intravenous gammaglobulin (IVIG), or blood products
Receipt of any investigational drug therapy within 30 days prior to randomization into the study or any biologic(s) within 5 half-lives of the agent prior to randomization into the study
Treatment with an oral or systemic burst of corticosteroids within 4 weeks prior to randomization into the study
Use of any chronic systemic immunosuppressive drugs, including oral corticosteroids within 4 weeks prior to randomization into the study
Current use of any oral or ophthalmic beta-adrenergic antagonist (for example, propranolol), must have been stopped 2 weeks prior to randomization into the study
Current allergy vaccination (immunotherapy)
History of anaphylaxis
Lung disease other than persistent asthma (for example, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease [COPD], tuberculosis [TB])
Acute illnesses or evidence of significant active infection, such as fever >=38.0 degrees Celsius [C] (>=100.5 degrees Fahrenheit [F]) at screening and up through time of the first dose of the investigational product
History of ingestion of untreated water in a location known to be infected with parasites, resulting in acute or chronic diarrhea; or an untreated parasitic infection within 1 month of randomization
Pregnancy (women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of the investigational product)
Lactating woman
Infection with human immunodeficiency virus (HIV)-1, HIV-2, or hepatitis A, B, or C virus
History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >= 1 year prior to randomization into the study
History of cigarette smoking >=10 pack years
History of alcohol abuse or drug abuse that required treatment <1 year prior to randomization into the study
Elective surgery planned during the study period
Evidence of any systemic disease or any finding upon physical examination, laboratory abnormality, chest x-ray (CXR), or electrocardiogram (ECG) that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study results
Employees of the clinical study site or any other individuals involved with the conduct of the study, or first degree family members of such individuals (that is, parents, siblings, or children)

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
Benralizumab 100 mg	Benralizumab 100 mg	Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
Benralizumab 25 mg	Benralizumab 25 mg	Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
Benralizumab 200 mg	Benralizumab 200 mg	Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.

Primary Outcome Measures

Name	Time	Method
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	Day 0 to Day 161	An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.

Secondary Outcome Measures

Name	Time	Method
Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab	Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Maximum Observed Serum Concentration (Cmax) for Benralizumab	Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab	Day 0, 1, 7, 28, 35, 56, 84, 112, and 161	Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.
Terminal Phase Elimination Half-Life (t1/2) for Benralizumab	Day 0, 1, 7, 28, 35, 56, 84, 112, and 161	Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.
Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit	Day 0, 28, 56, 84, 112, and 161